AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22070448 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-efficacy, response efficacy, and mothers' concern
Number of subjects: 386
Study 22070448 — intervention group
Group type: EXPERIMENTAL
Intervention: Content analysis of mothers' open-ended reasons for concern
Number of subjects: 386
Study 19224350 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent complainants reporting everyday events
Number of subjects: 374
Study 19224350 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent complainants reporting IPA
Number of subjects: 374
Study 19224350 — intervention group
Group type: COMPARATOR
Intervention: Inconsistent complainants reporting everyday events
Number of subjects: 374
Study 19224350 — intervention group
Group type: COMPARATOR
Intervention: Inconsistent complainants reporting IPA
Number of subjects: 374
Study 17182417 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-rated alliance
Number of subjects: 356
Study 17182417 — intervention group
Group type: COMPARATOR
Intervention: Therapist-rated alliance
Number of subjects: 356
Study 17182417 — intervention group
Group type: COMPARATOR
Intervention: Patient alliance ratings
Number of subjects: 356
Study 17182417 — intervention group
Group type: COMPARATOR
Intervention: Therapist alliance ratings
Number of subjects: 356
Study 15622016 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic Huntington's disease patients
Number of subjects: 0
Study 15622016 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic gene-positive Huntington's disease patients
Number of subjects: 0
Study 15622016 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HD group (symptomatic and asymptomatic)
Number of subjects: 0
Study 15622016 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting in 1's
Number of subjects: 0
Study 15622016 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of patients and controls retested after 6 months
Number of subjects: 0
Study 15622016 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 11250974 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg lefradafiban three times daily
Number of subjects: 64
Study 11250974 — intervention group
Group type: EXPERIMENTAL
Intervention: 45 mg lefradafiban three times daily
Number of subjects: 64
Study 11250974 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg lefradafiban three times daily
Number of subjects: 64
Study 11250974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 9827736 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI-spacer (salbutamol delivered via metered-dose inhaler plus spacer, 2.4 mg/h, 4 puffs at 10-minute intervals for 3 hours)
Number of subjects: 100
Study 9827736 — intervention group
Group type: COMPARATOR
Intervention: NEB (nebulized salbutamol, 6 mg/h, 1.5 mg at 15-minute intervals for 3 hours)
Number of subjects: 100
Study 9827736 — intervention group
Group type: EXPERIMENTAL
Intervention: MDI-spacer
Number of subjects: 100
Study 9827736 — intervention group
Group type: COMPARATOR
Intervention: NEB
Number of subjects: 100
Study 9827736 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 10150549 — intervention group
Group type: EXPERIMENTAL
Intervention: Early total enteral nutrition (TEN) with propofol sedation
Number of subjects: 45
Study 10150549 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN) with midazolam sedation
Number of subjects: 45
Study 2899511 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol (n = 20)
Number of subjects: 40
Study 2899511 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 20)
Number of subjects: 40
Study 29503004 — intervention group
Group type: EXPERIMENTAL
Intervention: cBMA (concentrated bone marrow aspirate)
Number of subjects: 37
Study 29503004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 26754759 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) of beta-lactam antibiotics
Number of subjects: 140
Study 26754759 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus (IB) dosing of beta-lactam antibiotics
Number of subjects: 140
Study 26754759 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion (CI) and Intermittent bolus (IB) dosing
Number of subjects: 140
Study 25757947 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 40
Study 25757947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23347503 — intervention group
Group type: EXPERIMENTAL
Intervention: Support program (intervention)
Number of subjects: 2082
Study 23347503 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 2082
Study 21913408 — intervention group
Group type: EXPERIMENTAL
Intervention: reamberin (800 ml/day for 8 days)
Number of subjects: 43
Study 21913408 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study 18489503 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccination
Number of subjects: 7861
Study 18489503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7861
Study 16458252 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session healthy dieting intervention
Number of subjects: 85
Study 16458252 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition (control)
Number of subjects: 85
Study 12740734 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental test on treadmill (TR) starting speed 6 or 8 km x h ‐1, increments 2 km x h ‐1 every 3 min
Number of subjects: 371
Study 12740734 — intervention group
Group type: EXPERIMENTAL
Intervention: Incremental test on bicycle ergometer (BE) starting at 50 Watt, increments 25 or 50 Watt every 3 min
Number of subjects: 371
Study 10780124 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Nicotine Patch
Number of subjects: 402
Study 10780124 — intervention group
Group type: EXPERIMENTAL
Intervention: Mint Snuff
Number of subjects: 402
Study 10780124 — intervention group
Group type: COMPARATOR
Intervention: Placebo Patch
Number of subjects: 402
Study 10780124 — intervention group
Group type: COMPARATOR
Intervention: No Mint Snuff
Number of subjects: 402
Study 8694014 — intervention group
Group type: EXPERIMENTAL
Intervention: HMCT formula (46 mol% 8:0 + 10:0)
Number of subjects: 20
Study 8694014 — intervention group
Group type: COMPARATOR
Intervention: LMCT formula (4.8 mol% 8:0 + 10:0)
Number of subjects: 20
Study 8694014 — intervention group
Group type: EXPERIMENTAL
Intervention: HMCT formula
Number of subjects: 20
Study 8398824 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum thymidine kinase (STK) < 6 U/l
Number of subjects: 547
Study 8398824 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum thymidine kinase (STK) > 11 U/l
Number of subjects: 547
Study 8398824 — intervention group
Group type: EXPERIMENTAL
Intervention: Melphalan treatment
Number of subjects: 547
Study 8398824 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCM treatment (adriamycin, BCNU, cyclophosphamide and melphalan)
Number of subjects: 547
Study 8398824 — intervention group
Group type: EXPERIMENTAL
Intervention: Low STK and SB2M
Number of subjects: 547
Study 8398824 — intervention group
Group type: EXPERIMENTAL
Intervention: High STK and SB2M
Number of subjects: 547
Study 3095558 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous parenteral nutrition (TPN)
Number of subjects: 46
Study 3095558 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition by jejunostomy (Jej)
Number of subjects: 46
Study 29617504 — intervention group
Group type: EXPERIMENTAL
Intervention: Roller pump (G1)
Number of subjects: 60
Study 29617504 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal pump (G2)
Number of subjects: 60
Study 27807041 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond-enriched diet (AED) (15% energy from almonds)
Number of subjects: 86
Study 27807041 — intervention group
Group type: COMPARATOR
Intervention: Nut-free diet (NFD)
Number of subjects: 86
Study 24032716 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training on the Biodex balance system
Number of subjects: 30
Study 24032716 — intervention group
Group type: COMPARATOR
Intervention: Traditional physical therapy exercise program
Number of subjects: 30
Study 23748506 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide once weekly (EQW)
Number of subjects: 1379
Study 21963124 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted socket suspension system (VASS)
Number of subjects: 20
Study 21963124 — intervention group
Group type: COMPARATOR
Intervention: Pin lock suspension system
Number of subjects: 20
Study 21963124 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill walking
Number of subjects: 20
Study 19033573 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic systematic lymphadenectomy
Number of subjects: 514
Study 19033573 — intervention group
Group type: COMPARATOR
Intervention: No lymphadenectomy
Number of subjects: 514
Study 17010864 — intervention group
Group type: EXPERIMENTAL
Intervention: Stop-and-chop
Number of subjects: 43
Study 17010864 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear preslice
Number of subjects: 43
Study 14506404 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Index of Problems (SIP)
Number of subjects: 153
Study 14506404 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Index of Problems (SIP) subscales
Number of subjects: 153
Study 10764703 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg, amoxicillin 1000 mg, and clarithromycin 500 mg twice daily for one week (H pylori eradication group)
Number of subjects: 83
Study 10764703 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg once daily for 12 months (H pylori positive group)
Number of subjects: 83
Study 10764703 — intervention group
Group type: COMPARATOR
Intervention: No treatment (H pylori negative control group)
Number of subjects: 83
Study 10764703 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori positive patients who remained H pylori positive (persistently H pylori positive group)
Number of subjects: 83
Study 8834976 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine 100 mg at bedtime
Number of subjects: 6
Study 8834976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1349028 — intervention group
Group type: COMPARATOR
Intervention: TRZ alone (5.0 mg)
Number of subjects: 222
Study 1349028 — intervention group
Group type: EXPERIMENTAL
Intervention: TRZ+MCTZ-2.5 mg
Number of subjects: 222
Study 1349028 — intervention group
Group type: EXPERIMENTAL
Intervention: TRZ+MCTZ-5.0 mg
Number of subjects: 222
Study 6146258 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study 6146258 — intervention group
Group type: COMPARATOR
Intervention: Anticoagulants, platelet-active drugs, lipid-lowering regimens, antiarrhythmic agents, physical exercise, calcium antagonists
Number of subjects: 0
Study 30654675 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TENS2
Number of subjects: 10
Study 30654675 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS
Number of subjects: 10
Study 30654675 — intervention group
Group type: COMPARATOR
Intervention: Other TENS groups
Number of subjects: 10
Study 31475572 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 18924
Study 31475572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18924
Study 29159864 — intervention group
Group type: EXPERIMENTAL
Intervention: Music intervention for 30 minutes during daytime rest
Number of subjects: 37
Study 29159864 — intervention group
Group type: COMPARATOR
Intervention: Control group (rest without music)
Number of subjects: 37
Study 26982282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream
Number of subjects: 75
Study 26982282 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream (for infants with BPD)
Number of subjects: 75
Study 24479699 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-based message with percentages
Number of subjects: 323
Study 24479699 — intervention group
Group type: COMPARATOR
Intervention: Bar graph with percentages
Number of subjects: 323
Study 24479699 — intervention group
Group type: COMPARATOR
Intervention: Combined form
Number of subjects: 323
Study 24479699 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to a message about genetically modified foods
Number of subjects: 323
Study 23386239 — intervention group
Group type: EXPERIMENTAL
Intervention: Single umbilical incision appendectomy
Number of subjects: 184
Study 23386239 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopy
Number of subjects: 184
Study 21105887 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg azithromycin for 3 days (U group)
Number of subjects: 55
Study 21105887 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week levofloxacin-azithromycin combination (P group)
Number of subjects: 55
Study 21105887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential treatment with both azithromycin and 4-week levofloxacin-azithromycin (U+P group)
Number of subjects: 55
Study 18599162 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended learning program (including e-learning) administered to 26 new nurses
Number of subjects: 50
Study 18599162 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face instruction in the classroom given to 24 new nurses
Number of subjects: 50
Study 15686240 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Gamma nail (SGN)
Number of subjects: 217
Study 15686240 — intervention group
Group type: COMPARATOR
Intervention: Medoff sliding plate (MSP)
Number of subjects: 217
Study 15686240 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SGN and MSP
Number of subjects: 217
Study 12188171 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glaucoma medications
Number of subjects: 0
Study 12188171 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 10711075 — intervention group
Group type: EXPERIMENTAL
Intervention: Lispro insulin
Number of subjects: 51
Study 10711075 — intervention group
Group type: COMPARATOR
Intervention: Control (regular insulin)
Number of subjects: 51
Study 7574775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal infusion of methotrexate (MTX) and 5-fluorouracil (5-FU)
Number of subjects: 20
Study 7574775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal infusion of methotrexate (MTX)
Number of subjects: 20
Study 7574775 — intervention group
Group type: COMPARATOR
Intervention: Intraarterial (IA) administration of MTX
Number of subjects: 20
Study 7574775 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) administration of MTX
Number of subjects: 20
Study 2322054 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative plasmapheresis
Number of subjects: 100
Study 2322054 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 71943 — intervention group
Group type: EXPERIMENTAL
Intervention: COMB (cyclophosphamide, vincristine, methyl CCNU, and bleomycin)
Number of subjects: 47
Study 71943 — intervention group
Group type: COMPARATOR
Intervention: CTX (cyclophosphamide alone)
Number of subjects: 47
Study 29709431 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-led counselling
Number of subjects: 27
Study 28024930 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine α1‐microglobulin (A1M)
Number of subjects: 491
Study 28024930 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocyte chemoattractant protein 1 (MCP‐1)
Number of subjects: 491
Study 28024930 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine procollagen type III and type I
Number of subjects: 491
Study 26076841 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylaria nigripes
Number of subjects: 104
Study 26076841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 23866314 — intervention group
Group type: EXPERIMENTAL
Intervention: Red yeast rice (RYR) extract for 8 weeks
Number of subjects: 52
Study 23866314 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 52
Study 23866314 — intervention group
Group type: EXPERIMENTAL
Intervention: Red yeast rice (RYR) extract
Number of subjects: 52
Study 23866314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 21751861 — intervention group
Group type: EXPERIMENTAL
Intervention: High-volume (170 mL) ropivacaine (0.2%) with epinephrine (1:100,000)
Number of subjects: 12
Study 21751861 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 12
Study 19504141 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel hydrogensulfate (CHS, 300 mg loading, followed by 75 mg/day)
Number of subjects: 21
Study 19504141 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel besylate (CB, 300 mg loading, followed by 75 mg/day)
Number of subjects: 21
Study 19504141 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel hydrogensulfate (CHS, 5 micromol/L ADP)
Number of subjects: 21
Study 19504141 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel besylate (CB, 5 micromol/L ADP)
Number of subjects: 21
Study 16372176 — intervention group
Group type: EXPERIMENTAL
Intervention: ThermoWrap garment (water-filled garment)
Number of subjects: 22
Study 16372176 — intervention group
Group type: COMPARATOR
Intervention: Standard care (warm air mattress with additional insulation)
Number of subjects: 22
Study 15504308 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole (RAB) 10 mg
Number of subjects: 177
Study 15504308 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (OME) 20 mg
Number of subjects: 177
Study 11096461 — intervention group
Group type: EXPERIMENTAL
Intervention: vit C‐1500 (1500 mg/day)
Number of subjects: 29
Study 11096461 — intervention group
Group type: COMPARATOR
Intervention: placebo control
Number of subjects: 29
Study 11096461 — intervention group
Group type: EXPERIMENTAL
Intervention: vit C‐500 (500 mg/day)
Number of subjects: 29
Study 9151231 — intervention group
Group type: EXPERIMENTAL
Intervention: Boron neutron capture therapy (BNCT) using p-boronophenylalanine (BPA) at a dose of 250 mg BPA/kg body weight during a 2-hour infusion.
Number of subjects: 18
Study 10146404 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive training program (3 days per week for 12 weeks)
Number of subjects: 60
Study 10146404 — intervention group
Group type: COMPARATOR
Intervention: Exercise walking program (3 days per week for 12 weeks)
Number of subjects: 60
Study 3533568 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (10 mg X 5)
Number of subjects: 9
Study 3533568 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 28914562 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular aquatic exercise
Number of subjects: 452
Study 28914562 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 452
Study 27600181 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist intervention
Number of subjects: 539
Study 27600181 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 539
Study 24666560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral global pelvic manipulation (GPM) technique (experimental group)
Number of subjects: 40
Study 24666560 — intervention group
Group type: COMPARATOR
Intervention: Sham (placebo) intervention (control group)
Number of subjects: 40
Study 21474911 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation plus controlled breathing
Number of subjects: 40
Study 21474911 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation
Number of subjects: 40
Study 20515219 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic psychotherapy with transference interpretation
Number of subjects: 100
Study 20515219 — intervention group
Group type: COMPARATOR
Intervention: Dynamic psychotherapy without transference interpretation
Number of subjects: 100
Study 18686770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber posts cemented with resin cement
Number of subjects: 40
Study 18686770 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium posts cemented with resin cement
Number of subjects: 40
Study 18686770 — intervention group
Group type: EXPERIMENTAL
Intervention: Titanium posts cemented with glass ionomer
Number of subjects: 40
Study 15816573 — intervention group
Group type: COMPARATOR
Intervention: Saline 2 mL (Group S)
Number of subjects: 75
Study 15816573 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg kg(‐1) (Group K)
Number of subjects: 75
Study 15816573 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 70 microg kg(‐1) (Group E)
Number of subjects: 75
Study 12460587 — intervention group
Group type: EXPERIMENTAL
Intervention: Androstadienone
Number of subjects: 37
Study 12460587 — intervention group
Group type: COMPARATOR
Intervention: Androstenol
Number of subjects: 37
Study 12460587 — intervention group
Group type: COMPARATOR
Intervention: Muscone
Number of subjects: 37
Study 10619585 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1 g elemental calcium, twice daily for 16 weeks)
Number of subjects: 32
Study 10619585 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily for 16 weeks)
Number of subjects: 32
Study 8739589 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) administration
Number of subjects: 10
Study 8739589 — intervention group
Group type: COMPARATOR
Intervention: Control group of older untreated affected siblings
Number of subjects: 10
Study 1921241 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous zinc supplementation for 8 weeks
Number of subjects: 25
Study 1921241 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7086609 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced convection incubator (air velocity 15 to 25 cm/second)
Number of subjects: 0
Study 7086609 — intervention group
Group type: COMPARATOR
Intervention: Still-air incubator (air velocity 0 to 2 cm/second)
Number of subjects: 0
Study 31023200 — intervention group
Group type: EXPERIMENTAL
Intervention: One suture-button device (OSB)
Number of subjects: 80
Study 31023200 — intervention group
Group type: COMPARATOR
Intervention: Two suture-button devices (TSB)
Number of subjects: 80
Study 28721578 — intervention group
Group type: EXPERIMENTAL
Intervention: Chair massage program
Number of subjects: 124
Study 28721578 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxing music sessions
Number of subjects: 124